Sunday 20 August 2017 The one stop source for free breaking news, expert analysis, and videos on AIM and LSE listed shares

Amryt - not a one trick pony!

By HotStockRockets | Monday 1 May 2017

Disclosure: Financial Investigative Media Limited, which is not owned by Tom Winnifrith but by a trust for his dependants, owns shares in companies mentioned in this article. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.

Many people think that the excitement about Amryt (AMYT) is down to its EB treatment where phase three trials are now underway. Well that is a lot of excitement but there is far more as the latest news makes clear.

Amryt has announced study results which evaluated the benefits of Lojuxta (lomitapide) in the treatment of Homozygous Familial Hypercholesterolaemia , a rare, life-threatening disease, which impairs the body's ability to remove LDL cholesterol from the blood. The study results confirmed that 'real-world' experience of a cohort of Italian patients show that Lojuxta is a very powerful cholesterol-lowering agent and, in particular, achieved greater efficacy than clinical trials of the drug.

Lojuxta is an MTP inhibitor approved for adjunctive treatment in adult patients with HoFH and was in-licenced by Amryt in early December 2016. Amryt's exclusive licence covers the European Economic Area , Middle East and North Africa , Turkey and Israel.

This is a company which is delivering real sales already. EB is the excitement but this is an added reason to hold. The shares now trade at 23p-25p, well up on our original tip but still below our target price to sell of 28p+.

Some brokers reckon the shares are worth 88p. Whatever. This is a very strong hold.

This article first appeared on HotStockRockets - it's always paying customers first. To catch a NEW red hot share tip from the HotStockRockets team, out shortly,  for just £5 click HERE

Filed under:

Never miss a story.

This area of the site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.

More on AMYT


Comments are turned off for this article.

Site by Everywhen